It is exciting to consider these mechanisms and therapeutic implications, for example, the development of IL-26 supplementation for IBD patients with elevated levels of Enterobacteriaceae, microbiota transfer in genetically predisposed IBD patients, and the use of IL-26 to control gut bacterial infections. The gene discussed is IL26; the disease is inflammatory bowel disease.